Notification

🚨 Trading Holiday 🚨

The NSE and BSE will remain closed for trading and settlement on Monday, April 14, 2025, on account of Dr. B. R. Ambedkar Jayanti.

Open a Free Demat Account

Pay ZERO maintenance charges for the first year, get free stock picks daily, and more.

Trade Now, Pay Later with up to 4x

Never miss a good trading opportunity due to low funds with our MTF feature.

Track Market Movers Instantly

Stay updated with real-time data. Get insights at your fingertips.

NSE BSE

Trade Nowopens in a new tab

Midland Polymers Ltd. Share Price

₹ 23.9 0.00 (0.00%)

Mar 03 2015 12:00 AM Packaging NSE: MIDPOLY

Midland Polymers Ltd. Share Price Update

As of the latest trading session, Midland Polymers Ltd. share price is currently at 23.9, which is up by 0.00 from its previous closing. Today, the stock has fluctuated between 23.90 and 23.90. Over the past year, Midland Polymers Ltd. has achieved a return of -41.70 %. In the last month alone, the return has been -0.41 %. Read More...

Midland Polymers Ltd. Performance

Day Range

Low23.90 High23.90

23.90

52 Week Range

Low .00 High 23.90

23.90

Midland Polymers Ltd. Share Price

531597

MIDPOLY

Compare to down-arrow

View

Display

Studies

No Data Available

Open Price

23.90 Prev. Close

23.90 Volume (Shares)

6.00 Total traded value

.00

Upper Circuit

1.05 Lower Circuit

.95

Note: The current prices & values are delayed, Loginopens in a new tab to your account for live updates.

Midland Polymers Ltd. Fundamentals

(Standalone)

Market Cap (Cr)	324.74
PE Ratio (TTM)	0.0
Book Value / Share	0.0
Beta	0.0

ROE	0.0%
EPS (TTM)	0.0
Dividend Yield	0.0%
Net Profit Qtr (Cr)	0.0

Midland Polymers Ltd. Financials

Key Results
Key Ratios
Balance sheet
Cash Flow
Competition

Revenue

Net income

Particulars	DEC 2024 (Values in Cr)
Revenue	0.00
Operating Expense	0.02
Net Profit	-0.02
Net Profit Margin (%)	0.00
Earnings Per Share (EPS)	-0.24
EBITDA	-0.02
Effective Tax Rate (%)	0.00

Particulars	SEP 2024 (Values in Cr)
Revenue	0.00
Operating Expense	0.03
Net Profit	-0.03
Net Profit Margin (%)	0.00
Earnings Per Share (EPS)	-0.41
EBITDA	-0.03
Effective Tax Rate (%)	0.00

Particulars	JUN 2024 (Values in Cr)
Revenue	0.00
Operating Expense	0.09
Net Profit	-0.09
Net Profit Margin (%)	0.00
Earnings Per Share (EPS)	-0.13
EBITDA	-0.09
Effective Tax Rate (%)	0.00

Particulars	MAR 2024 (Values in Cr)
Revenue	0.06
Operating Expense	0.02
Net Profit	0.03
Net Profit Margin (%)	50.00
Earnings Per Share (EPS)	0.05
EBITDA	0.03
Effective Tax Rate (%)	0.00

Particulars	DEC 2023 (Values in Cr)
Revenue	0.00
Operating Expense	0.03
Net Profit	-0.03
Net Profit Margin (%)	0.00
Earnings Per Share (EPS)	-0.40
EBITDA	-0.03
Effective Tax Rate (%)	0.00

Particulars	MAR 2024 (Values in Cr)
Revenue	0.06
Operating Expense	0.52
Net Profit	-0.46
Net Profit Margin (%)	-766.66
Earnings Per Share (EPS)	-6.83
EBITDA	-0.46
Effective Tax Rate (%)	0.00

Particulars	MAR 2023 (Values in Cr)
Revenue	0.00
Operating Expense	0.29
Net Profit	-0.29
Net Profit Margin (%)	0.00
Earnings Per Share (EPS)	-0.02
EBITDA	-0.29
Effective Tax Rate (%)	0.00

Particulars	MAR 2022 (Values in Cr)
Revenue	0.00
Operating Expense	0.14
Net Profit	-0.08
Net Profit Margin (%)	0.00
Earnings Per Share (EPS)	-0.01
EBITDA	-0.09
Effective Tax Rate (%)	11.11

Particulars	MAR 2021 (Values in Cr)
Revenue	0.00
Operating Expense	0.12
Net Profit	0.06
Net Profit Margin (%)	0.00
Earnings Per Share (EPS)	0.01
EBITDA	0.08
Effective Tax Rate (%)	25.00

Particulars	MAR 2020 (Values in Cr)
Revenue	0.00
Operating Expense	0.30
Net Profit	0.07
Net Profit Margin (%)	0.00
Earnings Per Share (EPS)	0.01
EBITDA	0.10
Effective Tax Rate (%)	0.00

Particulars	MAR 2017 (Values in Cr)
Book Value / Share	1.05
ROE %	0.58
ROCE %	0.58
Total Debt to Total Equity	0.01
EBITDA Margin	0.00

Particulars	MAR 2016 (Values in Cr)
Book Value / Share	1.04
ROE %	0.00
ROCE %	0.00
Total Debt to Total Equity	0.01
EBITDA Margin	0.00

Particulars	MAR 2015 (Values in Cr)
Book Value / Share	1.05
ROE %	1.01
ROCE %	0.65
Total Debt to Total Equity	0.01
EBITDA Margin	0.00

Particulars	MAR 2014 (Values in Cr)
Book Value / Share	1.04
ROE %	2.32
ROCE %	2.59
Total Debt to Total Equity	0.01
EBITDA Margin	0.00

Particulars	MAR 2024 (Values in Cr)
Book Value / Share	-27.35
ROE %	0.00
ROCE %	0.00
Total Debt to Total Equity	0.35
EBITDA Margin	-766.67

Particulars	MAR 2023 (Values in Cr)
Book Value / Share	1.04
ROE %	0.00
ROCE %	0.00
Total Debt to Total Equity	0.14
EBITDA Margin	0.00

Particulars	MAR 2017 (Values in Cr)
Book Value / Share	1.05
ROE %	0.58
ROCE %	0.61
Total Debt to Total Equity	0.00
EBITDA Margin	0.00

Particulars	MAR 2016 (Values in Cr)
Book Value / Share	1.04
ROE %	0.00
ROCE %	0.00
Total Debt to Total Equity	0.00
EBITDA Margin	0.00

Particulars	MAR 2015 (Values in Cr)
Book Value / Share	1.05
ROE %	1.01
ROCE %	0.66
Total Debt to Total Equity	0.00
EBITDA Margin	0.00

Particulars	MAR 2017 (Values in Cr)
Cash & Short Term Investments	0.23
Total Assets	17.13
Total Liabilities	17.13
Total Equity	14.32
Share Outstanding	135874700
Price to Book Ratio	0.00
Return on Assets (%)	0.44
Return on Capital (%)	0.53

Particulars	MAR 2016 (Values in Cr)
Cash & Short Term Investments	0.09
Total Assets	17.04
Total Liabilities	17.04
Total Equity	14.24
Share Outstanding	135874700
Price to Book Ratio	0.00
Return on Assets (%)	-0.63
Return on Capital (%)	-0.75

Particulars	MAR 2015 (Values in Cr)
Cash & Short Term Investments	0.14
Total Assets	17.00
Total Liabilities	17.00
Total Equity	14.35
Share Outstanding	135874700
Price to Book Ratio	22.76
Return on Assets (%)	0.99
Return on Capital (%)	1.16

Particulars	MAR 2014 (Values in Cr)
Cash & Short Term Investments	0.12
Total Assets	18.00
Total Liabilities	18.00
Total Equity	14.18
Share Outstanding	135874700
Price to Book Ratio	45.53
Return on Assets (%)	2.19
Return on Capital (%)	2.75

Particulars	MAR 2024 (Values in Cr)
Cash & Short Term Investments	0.00
Total Assets	0.47
Total Liabilities	0.47
Total Equity	-1.82
Share Outstanding	668760
Price to Book Ratio	0.00
Return on Assets (%)	-96.29
Return on Capital (%)	-100.21

Particulars	MAR 2023 (Values in Cr)
Cash & Short Term Investments	0.01
Total Assets	16.60
Total Liabilities	16.60
Total Equity	14.18
Share Outstanding	135874700
Price to Book Ratio	0.00
Return on Assets (%)	-1.73
Return on Capital (%)	-1.78

Particulars	MAR 2017 (Values in Cr)
Cash & Short Term Investments	0.01
Total Assets	16.76
Total Liabilities	16.76
Total Equity	14.20
Share Outstanding	135874700
Price to Book Ratio	0.00
Return on Assets (%)	0.45
Return on Capital (%)	0.54

Particulars	MAR 2016 (Values in Cr)
Cash & Short Term Investments	0.05
Total Assets	16.68
Total Liabilities	16.68
Total Equity	14.13
Share Outstanding	135874700
Price to Book Ratio	0.00
Return on Assets (%)	-0.64
Return on Capital (%)	-0.76

Particulars	MAR 2015 (Values in Cr)
Cash & Short Term Investments	0.08
Total Assets	16.64
Total Liabilities	16.64
Total Equity	14.23
Share Outstanding	135874700
Price to Book Ratio	22.76
Return on Assets (%)	1.01
Return on Capital (%)	1.18

Particulars	MAR 2015 (Values in Cr)
Net Income	0.10
Cash from Operations	-0.90
Cash from Investing	0.93
Cash from Financing	0.00
Net change in Cash	0.01
Free Cash Flow	-0.90

Particulars	MAR 2014 (Values in Cr)
Net Income	0.44
Cash from Operations	2.40
Cash from Investing	-2.38
Cash from Financing	-0.01
Net change in Cash	0.01
Free Cash Flow	2.41

Particulars	MAR 2024 (Values in Cr)
Net Income	-0.45
Cash from Operations	1.55
Cash from Investing	11.01
Cash from Financing	-12.55
Net change in Cash	0.00
Free Cash Flow	1.55

Particulars	MAR 2023 (Values in Cr)
Net Income	-0.28
Cash from Operations	0.00
Cash from Investing	0.00
Cash from Financing	0.00
Net change in Cash	0.00
Free Cash Flow	0.00

Company Name	Price	P/E	P/B	Market Cap	52 Week Low/High
COSMO FIRST LIMITED	556.60	12.01	1.02	1461.06	515.00 / 1084.10
EPL LIMITED	185.05	19.46	2.67	5913.45	169.85 / 289.70
GARWARE HI-TECH FILMS LTD	2654.20	19.81	2.76	6166.34	1513.25 / 5373.00
ROLLATAINERS LIMITED	1.50	0.00	-1.14	37.52	1.30 / 5.12

Company Name	Price	P/E	P/B	Market Cap	52 Week Low/High
COSMO FIRST LIMITED	556.60	19.61	1.19	1461.06	515.00 / 1084.10
EPL LIMITED	185.05	28.96	6.01	5913.45	169.85 / 289.70
GARWARE HI-TECH FILMS LTD	2654.20	19.07	2.84	6166.34	1513.25 / 5373.00
AGI GREENPAC LIMITED	768.30	17.12	2.60	4970.70	600.00 / 1300.00

Technicals

EMA & SMA
Resistance and Support
Price Change Analysis

Bullish Moving Averages -

Bearish Moving Averages -

5 Days 0.00
26 Days 0.00
10 Days 0.00
50 Days 0.00
12 Days 0.00
100 Days 0.00
20 Days 0.00
200 Days 0.00

0.0
PIVOT

First Resistance	0.0
Second Resistance	0.0
Third Resistance	0.0

First Support	0.0
Second Support	0.0
Third Support	0.0

RSI	0.0
MACD	0.0
Commodity Channel Index (CCI)	0.0

ADX	0.0
Williams % R	0.0

Midland Polymers Ltd. Future

Future: Price

25 May

0 100 200 300 400 500 600

Discount/Premium

25 May

0 1 2 3 4 5 6 7

Active Calls

25 May

0 500 1000 1500 2000 2500 3000

Active Puts

25 Jul

0 500 1000 1500 2000 2500

Stock Holding

View Live Stock Screeners

Holding

Public

94.34 Promoter Holdings

5.65 FII

0.0 DII

0.0 Promoter Shares(Pledge Percentage)

0.0

Name	Category	Shares	Shares%
Sanivarapu Jhansi	Public Shareholding	300000.0	44.86
Lakshmi Priya Vanguru Darshini	Public Shareholding	125000.0	18.69
Aditi Vishwanath Sajjanar	Public Shareholding	47300.0	7.07
Sreedar Reddy G	Shareholding of Promoter and Promoter Group	37850.0	5.66
Sushant Mohan Lal	Public Shareholding	25000.0	3.74
Prem Kumar Bajaj	Public Shareholding	10000.0	1.5

Midland Polymers Ltd.

Ex-Date	Dividend Amt.	Dividend Type	Record Date	Instrument Type

Ex-Date	Ex-Bonus	Ratio
2013-06-11	2013-06-10	1:1

Ex-Date	Old FV	NEW FV	Record Date
2013-06-10	10.0	1.0	2013-06-11

Learn More About Stocks

Dr Reddy’s Denies Workforce Reduction Claims Amid Cost-Cut Rumours

Dr Reddy’s Laboratories rejects claims of reducing workforce costs by 25%, asserting no such plans or internal directives.

15 Apr, 2025 | 3 Min. read

Glenmark, Sun Pharma, Zydus Recall Drugs in US over Compliance Issues

Glenmark, Sun Pharma, and Zydus recall multiple drug batches in the US following manufacturing deviations and contamination concerns as per USFDA enforcement reports.

15 Apr, 2025 | 3 Min. read

HAL Denies Selecting PwC for R&D Benchmarking Amid Ongoing Bids

HAL clarifies no consultancy firm has been finalised for R&D benchmarking amid social media buzz about PwC. Selection process still ongoing via GeM portal.

15 Apr, 2025 | 3 Min. read

Aurobindo Pharma Gets USFDA Nod for Generic Xarelto 2.5mg Tablets

Aurobindo Pharma receives USFDA approval to launch generic Xarelto 2.5mg in Q1 FY26, targeting $447 million US market; higher strengths also gain tentative nod.

15 Apr, 2025 | 3 Min. read

IndiGo Becomes World’s Most Valuable Airline With $23.4 Billion Market Cap

IndiGo surpasses global peers to become the most valuable airline by market cap at $23.4 billion, pushing InterGlobe Aviation share price to record highs in 2025.

11 Apr, 2025 | 3 Min. read

SRF Ltd. Commissions New Agrochemical Unit in Dahej Worth Rs.239 Crore

SRF Ltd. starts new agrochemical facility in Dahej, Gujarat with Rs.239 crore investment. Phase 1 operational, full commissioning set for April 2025.

11 Apr, 2025 | 3 Min. read

Tata Motors’ JLR India Achieves Record Sales in FY25 at 6,183 Units

JLR India posts record-breaking FY25 retail sales of 6,183 units, up 40%. Defender leads growth, boosting Tata Motors share price sentiment.

11 Apr, 2025 | 4 Min. read

Biocon Gets USFDA Approval for Jobevne, Expands Oncology Portfolio

Biocon Biologics receives USFDA nod for cancer drug Jobevne, a bevacizumab biosimilar. Oncology portfolio in US grows, boosting Biocon Ltd. share price outlook.

11 Apr, 2025 | 3 Min. read